Cue Biopharma Appoints Lucinda Warren as Interim President and CEO

Cue Biopharma (CUE) has appointed Lucinda Warren as interim president and CEO, succeeding Usman Azam who stepped down from his roles. Warren brings over 30 years of pharmaceutical and biotechnology experience and has been instrumental in executing key strategic transactions for the company.

By Maham Fatima Mon, April 20, 2026 at 5:15 PM GMT+3 2 min read · Yahoo Finance · April 20, 2026, 14:15 UTC

Cue Biopharma Appoints Lucinda Warren as Interim President and CEO

Tickers: $BIO $CUE $JNJ

Topics: Biopharma Clinical Trials Cue Biopharma CUE-401 Leadership Change

Read the full article at Yahoo Finance

More World news

Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC
Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC